Sorafenib Market Development Trends And Key Driving Factors Analysis Report By 2025
“Global Sorafenib Market is classified on the basis of treatment and geography. Sorafenib (Nexavar) is an orally-active multikinase inhibitor. It blocks the action of an abnormal protein that indicates cancer cells to grow. This slows down or stops the growth of cancer cells (tumors). It also slows down the growth of new-fangled blood vessels within the tumor.”
Global Sorafenib Market is classified on the basis of treatment and geography. Sorafenib (Nexavar) is an orallyactive multikinase inhibitor. It blocks the action of an abnormal protein that indicates cancer cells to grow. This slows down or stops the growth of cancer cells (tumors). It also slows down the growth of new-fangled blood vessels within the tumor. Sorafenib is used for treating advanced renal cell carcinoma (RCC is a kind of cancer that begins with the kidneys). Sorafenib is also used for treating hepatocellular carcinoma (a kind of liver cancer) that can’t be treated with surgery and a certain kind of thyroid cancer that has spread to the other parts of the body and can’t be treated with radioactive iodine. Sorafenib may cause side effects such as tiredness, weakness, skin redness, hair loss, itching, dry or peeling skin, loss of appetite, constipation, diarrhoea, dry mouth, weight loss, joint pain, numbness, pain or tingling in hands or feet and headache. In addition, some side effects can be serious such as unusual bruising or bleeding, black or tarry stools, bloody vomit, chest pain, confusion, changes in vision, dark urine, red blood in stools, vomiting material that looks like coffee grounds, severe stomach pain, shortness of breath, dizziness, sudden severe headache, seizures, mouth sores, yellowing of the skin or eyes, etc. The key factor that propels the growth of the Sorafenib Market includes increasing prevalence of cancer. Browse Full Research Report @ https://www.millioninsights.com/industry-reports/sorafenib-market